Detalhe da pesquisa
1.
Lung microenvironments harbor Mycobacterium tuberculosis phenotypes with distinct treatment responses.
Antimicrob Agents Chemother
; 67(9): e0028423, 2023 09 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37565762
2.
Drug distribution and efficacy of the DprE1 inhibitor BTZ-043 in the C3HeB/FeJ mouse tuberculosis model.
Antimicrob Agents Chemother
; 67(11): e0059723, 2023 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37791784
3.
Combination of Mycobacterium tuberculosis RS Ratio and CFU Improves the Ability of Murine Efficacy Experiments to Distinguish between Drug Treatments.
Antimicrob Agents Chemother
; 66(4): e0231021, 2022 04 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-35311519
4.
Comparative Analysis of Pharmacodynamics in the C3HeB/FeJ Mouse Tuberculosis Model for DprE1 Inhibitors TBA-7371, PBTZ169, and OPC-167832.
Antimicrob Agents Chemother
; 65(11): e0058321, 2021 10 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34370580
5.
Spectinamide MBX-4888A exhibits favorable lesion and tissue distribution and promotes treatment shortening in advanced murine models of tuberculosis.
bioRxiv
; 2024 May 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38798577
6.
Mycobacterium tuberculosis precursor rRNA as a measure of treatment-shortening activity of drugs and regimens.
Nat Commun
; 12(1): 2899, 2021 05 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34006838
7.
Digital Image Analysis of Heterogeneous Tuberculosis Pulmonary Pathology in Non-Clinical Animal Models using Deep Convolutional Neural Networks.
Sci Rep
; 10(1): 6047, 2020 04 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32269234